Tilray, Inc. TLRY said Thursday that it has received approval from the United State government to import CBD and has successfully brought in a shipment to support two New York University School of Medicine clinical trials.
The trials aim to test CBD as a treatment for patients with alcohol use disorder, or AUD, and post-traumatic stress disorder with AUD.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
Tilray’s GMP-certified, capsule-based CBD formulation will be used in the studies.
The double-blind studies will be led by NYU psychiatry professor Michael Bogenschutz, M.D. and Charles Marmar, M.D., the Lucius N. Littauer professor of psychiatry and chair of the department of psychiatry at NYU.
Bogenschutz will oversee the study on AUD. Marmar will lead the AUD and PTSD study.
Recruitment for both trials is expected to begin this summer.
Tilray shares were trading higher by 1.26% at $42.46 at the time of publication Thursday.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
